Formulation design and evaluation of amorphous ABT-102 nanoparticles

International Journal of Pharmaceutics

Volumn 498, Issue 1-2, 2016, Pages 153-169

  Jog, Rajan ^a   Kumar, Sumit ^a   Shen, Jie ^a   Jugade, Nital ^b   Thiam Tan, David Cheng ^b   Gokhale, Rajeev ^b   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b ABBVIE INC   (United States)

Author keywords

Amorphous nanoparticles; DoE; In vitro dissolution testing; Spray drying

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; AMORPHOUS NANOPARTICLE; DODECYL SULFATE SODIUM; NANOPARTICLE; POVIDONE; TREHALOSE; UNCLASSIFIED DRUG; INDAZOLE DERIVATIVE; UREA;

AQUEOUS SOLUTION; ARTICLE; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; HUMIDITY; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICROSCOPY; MOISTURE; PARTICLE SIZE; PRIORITY JOURNAL; SPRAY DRYING; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; MEDICINAL CHEMISTRY; PRECLINICAL STUDY; PROCEDURES; SYNTHESIS; X RAY DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; INDAZOLES; NANOPARTICLES; PARTICLE SIZE; UREA; X-RAY DIFFRACTION;

EID: 84951063374     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.12.033     Document Type: Article

References (26)

1. C. Bruce, K.A. Fegely, A.R. Rajabi-Siahboomi, and J.W. McGinity Crystal growth formation in melt extrudates Int. J. Pharm. 341 2007 162 172
2. X. Chen, T.J. Young, M. Sarkari, R.O. Williams, and K.P. Johnston Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution Int. J. Pharm. 242 2002 3 14
3. W.L. Chiou, and S. Riegelman Oral absorption of griseofulvin in dogs: increased absorption viasolid dispersion in polyethylene glycol 6000 J. Pharm. Sci. 59 1970 937 942
4. R.S. Dhumal, S.V. Biradar, S. Yamamura, A.R. Paradkar, and P. York Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability Eur. J. Pharm. Biopharm. 70 2008 109 115
5. B.C. Hancock, and M. Parks What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17 2000 397 404
6. A. Homayouni, F. Sadeghi, J. Varshosaz, H.A. Garekani, and A. Nokhodchi Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques Colloids Surf. B Biointerf. 122 2014 591 600
7. J.P. Hughes, S. Rees, S.B. Kalindjian, and K.L. Philpott Principles of early drug discovery Br. J. Pharmacol. 162 2011 1239 1249
8. N.K. Jain, and I. Roy Effect of trehalose on protein structure Protein Sci. 18 2009 24 36
9. J.A.H. Junghanns, and R.H. Muller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295
10. S. Kumar, J. Shen, and D.J. Burgess Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole J. Control. Release 192 2014 95 102
11. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
12. G.G. Liversidge, and K.C. Cundy Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs. 1. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs Int. J. Pharm. 125 1995 91 97
13. E.M. Merisko-Liversidge, and G.G. Liversidge Drug nanoparticles: formulating poorly water-soluble compounds Toxicol. Pathol. 36 2008 43 48
14. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120
15. S.A. Mousa, and D.J. Bharali Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications Cancers 3 2011 2888 2903
16. P. Narayan, W. Porter, M. Brackhagen, and C. Tucker Polymers and surfactants A. Newman, Pharmaceutical Amorphous Solid Dispersions 2015 John Wiley & Sons, Inc. Hoboken, New Jersey 42 84
17. S. Ohtake, and Y.J. Wang Trehalose: current use and future applications J. Pharm. Sci. 100 2011 2020 2053
18. S. Patnaik, S.K. Aditha, T. Rattan, and V. Kamisetti Aceclofenac-soluplus® nanocomposites for increased bioavailability Soft Nanosci. Lett. 5 2015 13
19. R. Peagram, R. Gibb, and K. Sooben The rational selection of formulations for preclinical studies: an industrial perspective Bull. Tech. Gattefossé 98 2005 53 64
20. H.M. Rainer, and A.H. Junghanns Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs V.P. Torchilin, Nanoparticulates as Drug Carriers 2006 Imperial College Press London 307 324
21. A. Serajuddin Solid dispersion of poorly water†soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
22. B. Sun, and Y. Yeo Nanocrystals for the parenteral delivery of poorly water-soluble drugs Curr. Opin. Solid State Mater. Sci. 16 2012 295 301
23. W. Thomson 4. On the equilibrium of vapour at a curved surface of liquid Proceedings of the Royal Society of Edinburgh 7 1872 63 68
24. S.R.K. Vaka, M.M. Bommana, D. Desai, J. Djordjevic, W. Phuapradit, and N. Shah Excipients for amorphous solid dispersions N. Shah, H. Sandhu, D.S. Choi, H. Chokshi, A.W. Malick, J.M. Rathbone, Amorphous Solid Dispersions, Theory and Practice 2014 Springer Controlled Release Society, New York 123 164
25. J.-X. Wang, Q.-X. Zhang, Y. Zhou, L. Shao, and J.-F. Chen Microfluidic synthesis of amorphous cefuroxime axetil nanoparticles with size-dependent and enhanced dissolution rate Chem. Eng. J. 162 2010 844 851
26. W.-Z. Zhu, J.-X. Wang, L. Shao, H.-X. Zhang, Q.-X. Zhang, and J.-F. Chen Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor Int. J. Pharm. 395 2010 260 265